MARKET

RYTM

RYTM

Rhythm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

28.98
-3.02
-9.44%
Closed 19:50 12/03 EST
OPEN
31.81
PREV CLOSE
32.00
HIGH
32.29
LOW
28.67
VOLUME
758.01K
TURNOVER
--
52 WEEK HIGH
34.27
52 WEEK LOW
12.99
MARKET CAP
1.28B
P/E (TTM)
-9.5745
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Biotech Stock Roundup: BIIB & SAGE Alliance, MRNA, BNTX Coronavirus Updates & More
Collaborations, and pipeline and regulatory updates take centerstage in the biotech sector as Moderna (MRNA) and BioNTech (BNTX) provide key updates.
Zacks · 1d ago
The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 1)
Benzinga · 1d ago
Rhythm (RYTM) Up on FDA Approval of Weight Management Drug
Rhythm's (RYTM) stock gains as FDA approves its lead product candidate for chronic weight management.
Zacks · 3d ago
Morgan Stanley Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $33
Morgan Stanley maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and raises the price target from $30 to $33.
Benzinga · 3d ago
How This Small Biotech Is Targeting Obesity And Why Shares Are Surging
Investor's Business Daily · 6d ago
Mid-Day Market Update: Nasdaq Surges 100 Points; Sorrento Therapeutics Shares Spike Higher
Midway through trading Friday, the Dow traded up 0.04% to 29,883.70 while the NASDAQ rose 0.86% to 12,197.94. The S&P also rose, gaining 0.17% to 3,635.88.
Benzinga · 6d ago
RIOT, NVAX, MARA and SOL among midday movers
Gainers: SCWorx (WORX) +80%.FreightCar America (RAIL) +48%.ReneSola (SOL) +44%.Oramed Pharmaceuticals (ORMP) +40%.Apex Technology Acquisition (APXT) +30%.Kaleyra (KLR) +29%.Rhythm Pharmaceuticals (RYTM) +27%.Aurora Mobile (JG) +27%.Novavax (NVAX) +20%.Arcturus Therapeutics (ARCT) +20%.Losers: R. R. Donnelley & Sons
Seekingalpha · 6d ago
SCWorx, Oramed Pharmaceuticals leads healthcare gainers; AnPac Bio-Medical Science, Sientra among major losers
Gainers: SCWorx (WORX) +90%, Oramed Pharmaceuticals (ORMP) +31%, Rhythm Pharmaceuticals (RYTM) +19%, Genfit (GNFT) +15%, Verastem (VSTM) +13%.Losers: AnPac Bio-Medical Science (ANPC) -11%, Sientra (SIEN) -9%, Alphatec Holdings (ATEC) -5%, Metacrine (MTCR) -4%.
Seekingalpha · 6d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RYTM. Analyze the recent business situations of Rhythm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RYTM stock price target is 36.00 with a high estimate of 43.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 159
Institutional Holdings: 48.57M
% Owned: 109.87%
Shares Outstanding: 44.20M
TypeInstitutionsShares
Increased
25
314.07K
New
40
120.35K
Decreased
37
2.36M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.41%
Pharmaceuticals & Medical Research
+0.49%
Key Executives
Chairman/President/Chief Executive Officer/Director
David Meeker
Chief Financial Officer
Hunter Smith
Executive Vice President
Jennifer Chien
Chief Scientific Officer
Lex H.T. Van der Ploeg
Executive Vice President
Yann Mazabraud
Independent Director
Stuart Arbuckle
Independent Director
Todd Foley
Other
Fred Fiedorek
Independent Director
Jennifer Good
Independent Director
Christophe Jean
Independent Director
Edward Mathers
Independent Director
David McGirr
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About RYTM
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity. Setmelanotide serves as replacement therapy for the treatment of melanocortin-4, or MC4, pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity. The Company also focused on obesity related to six single gene-related, or monogenic, MC4 pathway deficiencies pro-opiomelanocortin, or POMC, leptin receptor, or LepR, Bardet-Biedl syndrome, Alstrom syndrome, POMC heterozygous, and POMC epigenetic disorders.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Rhythm Pharmaceuticals Inc stock information, including NASDAQ:RYTM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RYTM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RYTM stock methods without spending real money on the virtual paper trading platform.